Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Immunovaccine appoints new audit chair

This article was originally published in Scrip

Executive Summary

Immunovaccine Inc, a Canadian vaccine development company, has appointed James Hall to its Board of Directors. Mr Hall will serve as chair of the audit committee, bringing over 25 years' experience in finance and investment to the role. He currently serves as president and CEO of James Hall Advisors, and has held previous roles in both senior and board positions at Working Ventures Canadian Fund, Global Credit Pref Corp, and Adventus Intellectual Property Inc. Mr Hall will work with the board to progress Immunovaccine's DepoVax vaccine delivery technology into the clinic, as well as to build shareholder value. He has been granted 50,000 stock options, which have a term of five years, under Immunovaccine's stock option plan.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts